Table 1.

Trials evaluating nitroimidazoles as radiosensitizers, sorted by publication year

Author	Year	Agent	Dose	n	Radiation regimen	Results
Urtasun et al. [5]	1976	Metronidazole	6 g/m2 3 times a week	36	3000 rads in 9 fractions (60Co), three times a week	Median TTP: 4.5 months Median OS: 26 weeks
Fulton et al. [6]	1984	Misonidazole	1.25 g/m2 3 times weekly	128 (89)	58 Gy in 30 fractions (CF) vs 61.41 Gy in 69 fractions (3 × daily HFRT)	Median OS: 50 weeks (HFRT + MISO) vs 29 weeks (CF) vs 45 weeks (HFRT)
Stadler et al. [7]	1984	Misonidazole	2.1–2.7 g/m2 twice a week	45	66.5 Gy in 31 fractions	Median OS 13.8 months (vs 9.8 months RT alone)
Coleman et al. [9]	1992	Etanidazole	8–24 g/m2 continuous over 48–96 h	78 (42)	10 Gy/day brachytherapy	MTD of 96 h infusion is 23 g/m2
Riese et al. [10]	1994	Etanidazole	10–36 g/m2 continuously	70 (51)	40 Gy in 20 fractions bid, +20 Gy in 10 fractions vs 50 Gy 125I‑Brachy (4–5 fx)	MTD: 26 g/m2 for Brachytherapy, 34 g/m2 for External Beam Radiotherapy (EBRT)
Chang et al. [12]	1998	Etanidazole	10–36 g/m2 continuously	70 (51)	40 Gy in 20 fractions bid, +20 Gy in 10 fractions vs 50 Gy 125I‑Brachy (4–5 fx)	Median OS: 1.1 years (GBM)
Marcus et al. [11]	2003	Etanidazole	1.8–2.4 g/m2 daily	18	63–66 Gy in 42–44 fractions bid	MTD: 42 g/m2 in children with brain stem glioma

n = number of patients included (number of patients with glioblastoma in parentheses if multiple entities were included)